MGTX Stock Analysis: MeiraGTx Holdings | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 1.228m USD | 12M Return: 78% | KYG596651029 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 10.0M
Qual. Beats: 1
Rev. Trend: 90.8%
Qual. Beats: 1
Warnings
Tailwinds
Seasonality 8.1 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
MeiraGTx Holdings plc is a clinical-stage genetic medicines company developing gene therapies for serious diseases, with its lead programs targeting ocular disorders, neurodegenerative conditions, and xerostomia. Its clinical pipeline spans multiple Phase 1/2 and Phase 2 trials-including AAV-AQP1 for radiation-induced xerostomia and Sjogrens syndrome, AAV-GAD for Parkinsons disease, AAV-RPE65 for RPE65-associated retinal dystrophy, and AAV-CNGB3/AAV-CNGA3 for achromatopsia-while preclinical work addresses additional inherited retinal diseases, amyotrophic lateral sclerosis, Alzheimers disease, and age-related macular degeneration. The company also operates a riboswitch platform for metabolic peptide delivery and a cell therapy program aimed at oncology, autoimmune disease, and intractable pain.
The business model relies on a partnership-driven approach, with notable collaborations including Johnson & Johnson Innovative Medicine for inherited retinal disease gene therapies and Hologen Limited for CNS-focused programs such as AAV-GAD (Parkinsons) and AAV-BDNF (genetic obesity). Founded in 2015 and headquartered in New York, MeiraGTx is classified within the Biotechnology sub-industry, a sector where pre-revenue companies typically depend on capital raises, milestone payments, and strategic alliances to fund costly late-stage clinical development before reaching commercialization.
- Johnson & Johnson partnership catalyzes retinal gene therapy milestones
- Phase 2 readouts pending across AAV-AQP1 xerostomia and AAV-GAD Parkinson programs
- In-house GMP manufacturing supports clinical supply and partnership economics
| Net Income: 79.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.02 > 0.02 and ΔFCF/TA 69.01 > 1.0 |
| NWC/Revenue: 40.31% < 20% (prev -16.75%; Δ 57.07% < -1%) |
| CFO/TA 0.03 > 3% & CFO 13.7m > Net Income 79.0m |
| Net Debt (-18.5m) to EBITDA (196.2m): -0.09 < 3 |
| Current Ratio: 3.76 > 1.5 & < 3 |
| Outstanding Shares: last quarter (93.8m) vs 12m ago 16.40% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 133.6% > 50% (prev 19.08%; Δ 114.5% > 0%) |
| Interest Coverage Ratio: 14.75 > 6 (EBIT TTM 184.0m / Interest Expense TTM 12.5m) |
| A: 0.40 (Total Current Assets 218.3m - Total Current Liabilities 58.1m) / Total Assets 396.4m |
| B: -1.77 (Retained Earnings -701.8m / Total Assets 396.4m) |
| C: 0.62 (EBIT TTM 184.0m / Avg Total Assets 297.6m) |
| D: 1.19 (Book Value of Equity 215.6m / Total Liabilities 180.7m) |
| Altman-Z'' = 2.29 = BBB |
| DSRI: 0.62 (Receivables 44.3m/6.79m, Revenue 397.5m/37.9m) |
| GMI: 0.27 (GM 26.56% / 97.19%) |
| AQI: 2.03 (AQ_t 0.11 / AQ_t-1 0.05) |
| SGI: 10.48 (Revenue 397.5m / 37.9m) |
| TATA: 0.16 (NI 79.0m - CFO 13.7m) / TA 396.4m) |
| Beneish M = 3.43 (Cap -4..+1) = D |
As of September 18, 2026, the stock is trading at USD 13.05 with a total of 953,000 shares traded. Over the past week, the price has changed by +1.56%, over one month by -5.23%, over three months by +25.36% and over the past year by +78.04%.
Current recommended Stop Loss: 12.10 (which is 7.3% or 1.6 ATR below the current price).
MeiraGTx Holdings has received a consensus analysts rating of 4.60. Therefore, it is recommended to buy MGTX.
- StrongBuy: 3
- Buy: 2
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 29.4 | 125.5% |
P/E Trailing = 14.7011
P/E Forward = 64.1026
P/S = 3.0903
P/B = 5.7005
Revenue TTM = 397.5m USD
EBIT TTM = 184.0m USD
EBITDA TTM = 196.2m USD
Long Term Debt = 100.0m USD (from longTermDebt, last quarter)
Short Term Debt = 2.30m USD (from shortTermDebt, last quarter)
Debt = 124.6m USD (from shortLongTermDebtTotal, last quarter) + Leases 12.3m
Net Debt = -18.5m USD (calculated: Debt 124.6m - CCE 143.2m)
Enterprise Value = 1.21b USD (1.23b + Debt 124.6m - CCE 143.2m)
Interest Coverage Ratio = 14.75 (Ebit TTM 184.0m / Interest Expense TTM 12.5m)
EV/FCF = 191.8x (Enterprise Value 1.21b / FCF TTM 6.31m)
FCF Yield = 0.52% (FCF TTM 6.31m / Enterprise Value 1.21b)
FCF Margin = 1.59% (FCF TTM 6.31m / Revenue TTM 397.5m)
Net Margin = 19.87% (Net Income TTM 79.0m / Revenue TTM 397.5m)
Gross Margin = unknown ((Revenue TTM 397.5m - Cost of Revenue TTM 11.2m) / Revenue TTM)
Tobins Q-Ratio = 3.05 (Enterprise Value 1.21b / Total Assets 396.4m)
Interest Expense / Debt = 10.01% (Interest Expense 12.5m / Debt 124.6m)
Taxrate = 1.45% (2.36m / 163.0m)
NOPAT = 181.4m (EBIT 184.0m * (1 - 1.45%))
Current Ratio = 3.76 (Total Current Assets 218.3m / Total Current Liabilities 58.1m)
Debt / Equity = 0.58 (Debt 124.6m / totalStockholderEquity, last quarter 215.6m)
Debt / EBITDA = -0.09 (Net Debt -18.5m / EBITDA 196.2m)
Debt / FCF = -2.94 (Net Debt -18.5m / FCF TTM 6.31m)
Total Stockholder Equity = 27.8m (last 4 quarters mean from totalStockholderEquity)
RoA = 26.54% (Net Income 79.0m / Total Assets 396.4m)
RoE = 284.4% (Net Income TTM 79.0m / Total Stockholder Equity 27.8m)
RoCE = 144.0% (EBIT 184.0m / Capital Employed (Equity 27.8m + L.T.Debt 100.0m))
RoIC = 56.54% (NOPAT 181.4m / Invested Capital 320.8m)
WACC = 11.47% (E(1.23b)/V(1.35b) * Re(11.63%) + D(124.6m)/V(1.35b) * Rd(10.01%) * (1-Tc(0.01)))
Discount Rate = 11.63% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 93.77 | Cagr: 18.47%
[DCF] Terminal Value 65.33% ; FCFF base≈6.31m ; Y1≈6.34m ; Y5≈6.71m
[DCF] Fair Price = 0.90 (EV 68.2m - Net Debt -18.5m = Equity 86.7m / Shares 96.0m; r=11.47% [WACC]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 4.0 | # QB: 1
Revenue Correlation: 90.79 | Revenue CAGR: 221.4% | SUE: 4.0 | # QB: 1
EPS current Quarter (2026-09-30): EPS=-0.46 | Chg30d=+6.76% | Revisions=+40% | Analysts=2
EPS current Year (2026-12-31): EPS=0.51 | Chg30d=+135.37% | Revisions=+40% | GrowthEPS=+135.9% | GrowthRev=+314.7%
EPS next Year (2027-12-31): EPS=-1.39 | Chg30d=-1.70% | Revisions=+40% | GrowthEPS=-372.5% | GrowthRev=-80.0%
[Analyst] Revisions Ratio: +67% (up=6, down=0)